Open-label Extension of Study 20130173 of Denosumab in Children and Young Adults With Osteogenesis Imperfecta

Phase 3

Terminated

Conditions: Osteogenesis Imperfecta (OI)

Interventions: Drug: Alternative osteoporosis medications
Drug: Denosumab

Registration Number: NCT03638128

Lead Sponsor: Amgen

Brief Summary: To evaluate long-term safety of denosumab in children/young adults with pediatric osteogenesis imperfecta (OI) who completed the prior study 20130173 (NCT02352753).

Detailed Description: All participants who completed the prior denosumab study 20130173 (NCT02352753) were offered participation in this study (20170534). Participants could continue to receive denosumab once every 3 months (Q3M) or could receive denosumab once every 6 months (Q6M) or off-treatment observation only at the investigator's discretion. The study design allowed subjects to discontinue denosumab, resume denosumab, initiate alternative osteoporosis medication, discontinue alternative osteoporosis medication, or receive no treatment (observation only) at any time. Therefore results of this study were analyzed according to both baseline treatment and subsequent treatment trajectories.

Recruitment & Eligibility

Status: TERMINATED

Sex: All

Target Recruitment: 75

Inclusion Criteria

Subject has provided informed consent/assent prior to initiation of any Study 20170534 specific activities/procedures. Subject's legally acceptable representative has provided informed consent when the subject is legally too young to provide informed consent and the subject has provided written assent based on local regulations and/or guidelines prior to any study-specific activities/procedures being initiated.
Subject is currently/was enrolled in Study 20130173 and
- completed the 20130173 End of Study (EOS) visit (regardless of completing or ending investigational product early) OR
- did not reconsent/reassent to transition to 3-month dosing regimen on Study 20130173 OR
- early terminated from Study 20130173 as a result of meeting bone mineral density (BMD) Z-score investigational product stopping criteria.

Exclusion Criteria

Treatment with any prohibited proscribed medications while receiving denosumab. Eligibility into study treatment with alternative osteoporosis medication/s of investigator's choice, follow guidelines per the specific alternative osteoporosis medication/s selected. For subjects off-treatment (observation only), no prohibited medications apply.
Subjects currently receiving treatment in another investigational device or drug study other than Study 20130173. Other investigational procedures while participating in this study are excluded.
For subjects expected to receive investigational product (denosumab) at study day 1: Female subject is pregnant or breastfeeding or planning to become pregnant or breastfeed during treatment and for an additional 5 months after the last dose of denosumab. Females of childbearing potential (Tanner Stage greater than or equal to 2) should only be included in the study after a negative highly sensitive urine or serum pregnancy test. For study treatment with alternative osteoporosis medication/s of investigator's choice, follow guidelines per the specific alternative osteoporosis medication/s selected. For Subjects off-treatment (observation only), no exclusion applies.
For subjects expected to receive investigational product (denosumab) at study day 1: Female subjects of childbearing potential unwilling to practice true sexual abstinence (refrain from heterosexual intercourse) or use 1 highly effective method of contraception during treatment and for an additional 5 months after the last dose of investigational product (denosumab). For study treatment with alternative osteoporosis medication/s of investigator's choice, follow contraception guidelines per the specific alternative osteoporosis medication/s selected. For subjects not receiving any investigational product (observation only), no contraception required.
History or evidence of any other clinically significant disorder, condition or disease (with the exception of those outlined above) that, in the opinion of the investigator or Amgen physician, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion.

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Alternative Medications / Observational	Alternative osteoporosis medications	Participants who received non-denosumab alternative therapy during the study or who were not receiving any medication at baseline. Alternative osteoporosis medication(s) were determined at the investigator's discretion and per standard of care and local guidelines.
Denosumab 1 mg/kg Q6M	Denosumab	Participants who received at least 1 dose of 1 mg/kg denosumab administered once every 6 months (Q6M) by subcutaneous injection, but no Q3M denosumab during this study.
Denosumab 1 mg/kg Q3M	Denosumab	Participants who received at least one dose of 1 mg/kg denosumab administered once every 3 months (Q3M) by subcutaneous injection during this study.

Primary Outcome Measures

Name	Time	Method
Number of Participants With Abnormal Molar Eruption of the First or Second Molar Based on Radiological Findings	Baseline, month 12, and month 24	Participants underwent a visual inspection under natural light for the presence of the first and second molars. Participants were referred to a dentist to perform radiographic assessment of the unerupted molar(s) if: * A participant was age 7 to 12 years and appeared to have an unerupted upper or lower first molar (ie, not all 4 first molars were visible/detectable). * A participant was age 13 years or older and appeared to have an unerupted upper or lower (first or) second molar (ie, not all 4 first molars and all 4 second molars were visible/detectable). Abnormal molar eruptions includes the number of participants 7 to 12 years of age with 1st unerupted or partially erupted molars and participants 13 years of age or older with 2nd unerupted or partially erupted molars.
Number of Participants With Clinical Laboratory Toxicities Grade ≥ 3	From enrollment to end of study, including 24 weeks after last dose of denosumab for participants who received denosumab; the maximum time on study was 24 months	Laboratory abnormalities were graded according to the Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0. The grades refer to the severity of the finding: Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe or medically significant; Grade 4 = Life-threatening consequences, urgent intervention indicated.
Number of Participants With Clinically Significant Vital Sign Findings	From enrollment to end of study, including 24 weeks after last dose of denosumab for participants who received denosumab; the maximum time on study was 24 months	Vital sign measurements included systolic and diastolic blood pressure, heart rate, respiratory rate, and temperature. The investigator assessed vital sign results and determined whether any abnormal changes represented a clinically significant change from the participant's baseline values.
Number of Participants With Metaphyseal Index Z-score Above Age-appropriate Normal Range	Baseline, month 12 and month 24	Anteroposterior radiographs of both knees (unless prohibited by the presence of hardware such as implants) were used to calculate the metaphyseal index Z-score of each knee in participants with open growth plates; the knee selected for assessment during the study was the knee with the higher Z-score at baseline. The metaphyseal index (MI) was calculated by the central imaging vendor as the ratio of femoral width over distal femoral growth plate width, and the Z-score for each participant, relative to the participant's age as: MI Z-score = (participant value - mean)/SD, where mean and standard deviation (SD) are the corresponding values based on a reference population for the participant's age group at the time of the assessment. Metaphyseal index Z-score above age-appropriate normal range is defined as a MI Z-score \> 2.
Number of Participants With Adverse Events, Serious Adverse Events, and Adverse Events of Special Interest	From enrollment to end of study, including 24 weeks after last dose of denosumab for participants who received denosumab; the maximum time on study was 24 months.	A Serious Adverse Event is defined as any untoward medical occurrence that met at least 1 of the following serious criteria: * Resulted in death (fatal) * Immediately life-threatening * Required in-patient hospitalization or prolongation of existing hospitalization * Resulted in persistent or significant disability/incapacity * Was a congenital anomaly/birth defect * Other medically important serious event that may have jeopardized the participant or require medical or surgical intervention to prevent 1 of the outcomes listed above. Adverse events of special interest included hypocalcemia, hypersensitivity, bacterial cellulitis, osteonecrosis of the jaw (ONJ), hypercalcemia, and typical osteogenesis imperfecta (OI) femur fractures.
Number of Participants With Anti-denosumab Antibodies	From enrollment to end of study, including 24 weeks after last dose of denosumab for participants who received denosumab; the maximum time on study was 24 months	Blood samples were collected (from denosumab treated participants only) for the measurement of anti-denosumab binding antibodies. Samples positive for anti-denosumab binding antibodies were further tested for neutralizing antibodies.
Percent Change From Baseline in Mandibular Shaping Parameters	Baseline and month 12 and month 24	Lateral cephalogram was performed to enable assessment of mandibular shaping. The lateral cephalogram is a profile X-ray of the skull and soft tissues and is used to assess the relation of the teeth in the jaws, the relation of the jaws to the skull, and the relation of the soft tissues to the teeth and jaws. The following anatomical angles and dimensions were measured to evaluate the correct proportions of the mandible and its position relative to the skull/maxilla: Gonial angle; Sella-Nasion-A Point Angle (SNA angle); Sella-Nasion-B Point Angle (SNB angle); and A Point - Nasion-B Point Angle (ANB Angle).

Secondary Outcome Measures

Name	Time	Method
Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) Z-score	Baseline and months 6, 12, and 24	Bone densitometry assessments of the lumbar spine were performed using dual X-ray absorptiometry (DXA). The Z-score indicates the number of standard deviations away from the mean of an average person of the same age, sex, race, and weight. A Z-score of 0 is equal to the mean of the matched population, negative Z-scores indicate a BMD lower than the mean of the matched population, and positive Z-scores indicate a higher BMD than that of the matched population. A positive change from baseline indicates an improvement in lumbar spine BMD.
Change From Baseline in Total Hip BMD Z-score	Baseline, months 6, 12, and 24	Bone densitometry assessments of the hip were performed using dual X-ray absorptiometry (DXA). The Z-score indicates the number of standard deviations away from the mean of an average person of the same age, sex, race, and weight. A Z-score of 0 is equal to the mean of the matched population, negative Z-scores indicate a BMD lower than the mean of the matched population, and positive Z-scores indicate a higher BMD than that of the matched population. A positive change from baseline indicates an improvement in total hip BMD.
Change From Baseline in Femoral Neck BMD Z-score	Baseline and months 6, 12, and 24	Bone densitometry assessments of the femoral neck were performed using dual X-ray absorptiometry (DXA). The Z-score indicates the number of standard deviations away from the mean of an average person of the same age, sex, race, and weight. A Z-score of 0 is equal to the mean of the matched population, negative Z-scores indicate a BMD lower than the mean of the matched population, and positive Z-scores indicate a higher BMD than that of the matched population. A positive change from baseline indicates an improvement in femoral neck BMD.

Trial Locations

Locations (22): Birmingham Childrens Hospital
🇬🇧
Birmingham, United Kingdom
Perth Childrens Hospital
🇦🇺
Nedlands, Western Australia, Australia
Shriners Hospital for Children
🇨🇦
Montreal, Quebec, Canada
Azienda Ospedaliera Policlinico Umberto I
🇮🇹
Roma, Italy
The Hospital for Sick Children
🇨🇦
Toronto, Ontario, Canada
Uniklinik Köln
🇩🇪
Köln, Germany
Universite Catholique de Louvain Cliniques Universitaires Saint Luc
🇧🇪
Bruxelles, Belgium
Centre Hospitalier Universitaire de Bordeaux - Hopital Pellegrin
🇫🇷
Bordeaux Cedex, France
Childrens Hospital of Eastern Ontario
🇨🇦
Ottawa, Ontario, Canada
Childrens Hospital of Los Angeles
🇺🇸
Los Angeles, California, United States
Indiana University - Riley Hospital for Children
🇺🇸
Indianapolis, Indiana, United States
The Childrens Hospital at Westmead
🇦🇺
Westmead, New South Wales, Australia
Fakultni nemocnice Plzen
🇨🇿
Plzen, Czechia
Thomayerova nemocnice
🇨🇿
Praha 4, Czechia
Hopital Necker Enfants Malades
🇫🇷
Paris Cedex 15, France
Semmelweis Egyetem
🇭🇺
Budapest, Hungary
SPZOZ Centralny Szpital Kliniczny Uniwersytetu Medycznego w Lodzi
🇵🇱
Lodz, Poland
Hospital Sant Joan de Deu
🇪🇸
Esplugues de Llobregat, Cataluña, Spain
Bristol Royal Hospital for Children
🇬🇧
Bristol, United Kingdom
Hospital Universitari i Politecnic La Fe
🇪🇸
Valencia, Comunidad Valenciana, Spain
Royal Hospital for Children
🇬🇧
Glasgow, United Kingdom
Sheffield Childrens Hospital
🇬🇧
Sheffield, United Kingdom